CD276 and cancer: Specifically, patients with a higher CD276-positive cancer cell density exhibited significantly worse overall survival and recurrence-free survival in our cohort (HR = 2.8, P = 0.01, and HR = 7.52, P < 0.001, respectively) and in the validation cohort (HR = 2.4, P = 0.033, and HR = 3.7, P < 0.001, respectively).